ResMed Inc (ASX: RMD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResMed Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $54.30 billion
P/E Ratio 34.67
Dividend Yield 0.84%
Shares Outstanding 1.47 billion
Earnings per share 0.692
Dividend per share 0.31
Year To Date Return 47.71%
Earnings Yield 2.88%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ResMed Inc (ASX: RMD)
    Latest News

    Male hands holding Australian dollar banknotes, symbolising dividends.
    Dividend Investing

    Want the latest ResMed dividend? Here's what you need to do

    The cutoff for ResMed's latest payout is fast approaching.

    Read more »

    Excited group of friends sitting on sofa watching sports on TV and celebrating.
    Best Shares

    Top ASX shares to buy in November 2024

    These are the ASX stocks our Foolish writers say should be on your ticket right now!

    Read more »

    Man with a sleep apnoea mask on whilst sleeping.
    Healthcare Shares

    Why this fundie is backing ResMed shares in FY25

    There's plenty more upside, this fund says.

    Read more »

    A young woman smiles as she rides a zip line high above the trees.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Investors enjoyed a positive start to the trading week today.

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Share Gainers

    Why DroneShield, Newmont, ResMed, and Vulcan Energy shares are storming higher

    These shares are starting the week strongly. But why?

    Read more »

    A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Here's why brokers believe that now could be the time to snap up these stocks.

    Read more »

    Man standing on rock next to turquoise salt lagoon.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Do you own any of today's best shares?

    Read more »

    Rising share price chart.
    Share Gainers

    Why Aussie Broadband, HMC Capital, ResMed, and WiseTech shares are storming higher

    These shares are ending the week strongly. But why?

    Read more »

    A young man punches the air in delight as he reacts to great news on his mobile phone.
    Healthcare Shares

    ResMed shares jump 8% on stellar start to FY25

    This high-quality company continues to deliver the goods.

    Read more »

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Share Market News

    5 things to watch on the ASX 200 on Friday

    Will the market end the week on a high? Let's find out.

    Read more »

    Man holding a calculator with Australian dollar notes, symbolising dividends.
    How to invest

    Here's how I'd invest $200 a month and aim for $50,000 of annual passive income

    Getting paid without having to lift a finger? Sign me up!

    Read more »

    A happy boy with his dad dabs like a hero while his father checks his phone.
    Best Shares

    Top ASX shares for beginner investors to buy in October 2024

    Buying these ASX shares now could be a profitable way to kick off your wealth-building journey!

    Read more »

    Frequently Asked Questions

    Yes. As well as being listed on the ASX since November 1999, ResMed trades on the New York Stock Exchange under the ticker code NYSE: RMD.

    Yes, historically ResMed pays unfranked quarterly dividends each year. It does not offer a dividend reinvestment plan.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    14 Aug 2024 $0.0561 0.00% Final 19 Sep 2024
    08 May 2024 $0.0508 0.00% Interim 13 Jun 2024
    07 Feb 2024 $0.0517 0.00% Interim 14 Mar 2024
    08 Nov 2023 $0.0528 0.00% Interim 14 Dec 2023
    16 Aug 2023 $0.0524 0.00% Final 21 Sep 2023
    10 May 2023 $0.0460 0.00% Interim 15 Jun 2023
    08 Feb 2023 $0.0444 0.00% Interim 16 Mar 2023
    09 Nov 2022 $0.0466 0.00% Interim 15 Dec 2022
    17 Aug 2022 $0.0445 0.00% Final 22 Sep 2022
    11 May 2022 $0.0429 0.00% Interim 16 Jun 2022
    09 Feb 2022 $0.0410 0.00% Interim 17 Mar 2022
    10 Nov 2021 $0.0403 0.00% Interim 16 Dec 2021
    18 Aug 2021 $0.0412 0.00% Final 23 Sep 2021
    12 May 2021 $0.0354 0.00% Interim 17 Jun 2021
    10 Feb 2021 $0.0352 0.00% Interim 18 Mar 2021
    11 Nov 2020 $0.0378 0.00% Interim 17 Dec 2020
    19 Aug 2020 $0.0379 0.00% Final 24 Sep 2020
    13 May 2020 $0.0423 0.00% Interim 18 Jun 2020
    12 Feb 2020 $0.0406 0.00% Interim 19 Mar 2020
    06 Nov 2019 $0.0396 0.00% Interim 12 Dec 2019
    14 Aug 2019 $0.0403 0.00% Final 19 Sep 2019
    08 May 2019 $0.0371 0.00% Interim 13 Jun 2019
    06 Feb 2019 $0.0365 0.00% Interim 14 Mar 2019
    07 Nov 2018 $0.0356 0.00% Interim 13 Dec 2018
    15 Aug 2018 $0.0357 0.00% Final 20 Sep 2018
    09 May 2018 $0.0326 0.00% Interim 14 Jun 2018
    07 Feb 2018 $0.0315 0.00% Interim 15 Mar 2018
    08 Nov 2017 $0.0320 0.00% Interim 14 Dec 2017
    16 Aug 2017 $0.0308 0.00% Final 21 Sep 2017
    10 May 2017 $0.0313 0.00% Interim 15 Jun 2017
    08 Feb 2017 $0.0303 0.00% Interim 16 Mar 2017
    09 Nov 2016 $0.0303 0.00% Interim 15 Dec 2016
    17 Aug 2016 $0.0300 0.00% Final 22 Sep 2016
    18 May 2016 $0.0291 0.00% Interim 16 Jun 2016
    09 Feb 2016 $0.0295 0.00% Interim 17 Mar 2016
    17 Nov 2015 $0.0292 0.00% Interim 17 Dec 2015

    RMD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About ResMed Inc

    ResMed Inc (ASX: RMD) is a global leader in sleep technology. It develops, manufactures, and distributes medical devices – such as flow generators, CPAP masks, and accessories – and cloud-based software applications that diagnose, treat, and manage a range of respiratory disorders including sleep apnea, chronic obstructive pulmonary disease (COPD), and neuromuscular disease.

    It also provides software platforms to support professionals and caregivers to help patients in an out-of-hospital setting. The company operates in more than 140 countries, with manufacturing facilities in Australia, Singapore, France, and the United States. ResMed was established in Australia in 1989 but is now based in San Diego in the United States.

    RMD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Nov 2024 $37.00 $0.08 0.22% 844,991 $36.70 $37.00 $36.61
    31 Oct 2024 $36.92 $-0.40 -1.07% 1,351,839 $37.15 $37.15 $36.79
    30 Oct 2024 $37.32 $-0.59 -1.56% 1,964,018 $37.38 $37.51 $37.07
    29 Oct 2024 $37.91 $-1.16 -2.97% 2,324,802 $37.33 $37.91 $37.31
    28 Oct 2024 $39.07 $1.34 3.55% 1,199,727 $38.50 $39.13 $38.19
    25 Oct 2024 $37.73 $2.11 5.92% 1,785,265 $38.05 $38.67 $37.36
    24 Oct 2024 $35.62 $-0.13 -0.36% 1,040,104 $35.70 $35.93 $35.56
    23 Oct 2024 $35.75 $-0.18 -0.50% 579,543 $35.89 $36.07 $35.74
    22 Oct 2024 $35.93 $-0.09 -0.25% 977,081 $35.84 $36.05 $35.77
    21 Oct 2024 $36.02 $0.38 1.07% 754,122 $36.00 $36.23 $35.90
    18 Oct 2024 $35.64 $0.20 0.56% 997,505 $35.60 $35.82 $35.51
    17 Oct 2024 $35.44 $-0.15 -0.42% 925,503 $35.86 $36.00 $35.44
    16 Oct 2024 $35.59 $-0.33 -0.92% 652,560 $35.74 $35.87 $35.59
    15 Oct 2024 $35.92 $0.32 0.90% 496,902 $35.67 $35.98 $35.67
    14 Oct 2024 $35.60 $0.40 1.14% 476,737 $35.61 $35.74 $35.40
    11 Oct 2024 $35.20 $0.05 0.14% 560,536 $35.09 $35.35 $35.09
    10 Oct 2024 $35.15 $0.00 0.00% 513,552 $35.22 $35.48 $35.13
    09 Oct 2024 $35.15 $0.70 2.03% 888,180 $35.07 $35.20 $34.95
    08 Oct 2024 $34.45 $0.10 0.29% 591,226 $34.22 $34.50 $34.20
    07 Oct 2024 $34.35 $-0.31 -0.89% 484,059 $34.53 $34.66 $34.19
    04 Oct 2024 $34.66 $-0.10 -0.29% 1,301,537 $34.65 $34.82 $34.53
    03 Oct 2024 $34.76 $-0.16 -0.46% 838,836 $34.62 $34.83 $34.48

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Jul 2024 Christopher Roberts Issued 12,000 $611,400
    Issue of options. https://www.aspecthuntley.com.au/asxdata/20040709/pdf/00445695.pdf, usd$

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Peter Craig Farrell Non-Executive DirectorNon-Executive Chairman Jul 2002
    No profile reported in Annual Report.
    Mr Ronald R Taylor Non-Executive Director Jan 2005
    Mr Taylor is a director of Actavis, Inc. and Red Lion Hotels Corp. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation. In 1987, Mr. Taylor founded Pyxis Corporation where he served as chairman, president, and chief executive officer until its purchase by Cardinal Health, Inc., in 1996.
    Mr Richard Sulpizio Non-Executive Director Aug 2005
    Mr Sulpizio has served as president and chief executive officer of Qualcomm Enterprise Services. He currently serves as a senior advisor to Qualcomm Enterprise Services. Mr Sulpizio held various positions with Qualcomm during his 20-year tenure there, including president and chief operating officer. He served as a member of Qualcomm's board of directors from 2000 until 2007.
    Mr Michael J Farrell Chief Executive OfficerExecutive Director Mar 2013
    Mr Farrell was foundation director of Biomedical Engineering at the University of New South Wales where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. Since 2005, Dr Farrell has been a director of NuVasive, Inc. He also serves as the non-executive chair of QRxPharma.
    Ms Carol Burt Non-Executive Director Aug 2014
    No profile reported in Annual Report.
    Ms Karen Ruth Drexler Non-Executive Director Nov 2017
    No profile reported in Annual Report.
    Mr Jan De Witte Non-Executive Director May 2019
    Mr De Witte is the chief executive officer and member of the board of directors of Barco NV.
    Ms Harjit Gill Non-Executive Director Nov 2018
    No profile reported in Annual Report.
    Mr John Hernandez Non-Executive Director Nov 2021
    No profile reported in Annual Report.
    Mr Desney Tan Non-Executive Director Nov 2021
    No profile reported in Annual Report.
    Mr Christopher DelOrefice Non-Executive Director Aug 2024
    Mr DelOrefice, is the executive vice president and chief financial officer of Becton Dickinson and Company and has served in that role since September 2021. Previously, he served as Vice President, Investor Relations at Johnson & Johnson from August 2018 to September 2021 and Chief Financial Officer of North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018.
    Brett A. Sandercock Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    N/A 0 0.00%

    Profile

    since

    Note